Array
(
[id] => 1255
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1255.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend that for low, moderate and high thrombotic risk patients undergoing procedures requiring international normalised ratio (INR) less than 1.5, the time from last VKA intake to intervention should be 3 to 5 days; if INR is more than 1.5 on the day before surgery,5 mg oral vitamin K are recommended.（Evidence level: low；Recommendation grade: strong）
[laiyuan] => 对于接受手术的低、中、高血栓风险患者，要求INR＜1.5，末次服用VKA至手术的时间为3 ~ 5 d，如术前1天INR > 1.5，建议口服5mg维生素K。（证据级别：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于接受手术的低、中、高血栓风险患者，要求INR＜1.5，末次服用VKA至手术的时间为3 ~ 5 d，如术前1天INR > 1.5，建议口服5mg维生素K。（证据级别：低；推荐强度：强推荐）
We recommend that for low, moderate and high thrombotic risk patients undergoing procedures requiring international normalised ratio (INR) less than 1.5, the time from last VKA intake to intervention should be 3 to 5 days; if INR is more than 1.5 on the day before surgery,5 mg oral vitamin K are recommended.（Evidence level: low；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1256
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1256.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest against bridging of VKA with LMWH or UFH in low, moderate and high thrombotic risk patients; in very specific high-risk patients, the treatment should be based on case-by-case analysis.（Evidence level: low；Recommendation grade: moderate）
[laiyuan] => 对于低、中、高血栓风险患者，不建议桥接VKA与LMWH或UFH，对于非常特殊的高危患者，治疗应基于个案分析。（证据级别：低；推荐强度：中推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于低、中、高血栓风险患者，不建议桥接VKA与LMWH或UFH，对于非常特殊的高危患者，治疗应基于个案分析。（证据级别：低；推荐强度：中推荐）
We suggest against bridging of VKA with LMWH or UFH in low, moderate and high thrombotic risk patients; in very specific high-risk patients, the treatment should be based on case-by-case analysis.（Evidence level: low；Recommendation grade: moderate）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1257
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1257.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend that in patients with pre-operative VKA intake, VKA should be resumed within 24 h after the procedure, administering a LMWH in a prophylactic dose until the target INR is observed in two following measurements.（Evidence level: low；Recommendation grade: weak）
[laiyuan] => 对于术前服用VKA的患者，建议在术后24 h内恢复使用VKA，并给予LMWH预防剂量，直至术后两次INR达标。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于术前服用VKA的患者，建议在术后24 h内恢复使用VKA，并给予LMWH预防剂量，直至术后两次INR达标。（证据级别：低；推荐强度：弱推荐）
We recommend that in patients with pre-operative VKA intake, VKA should be resumed within 24 h after the procedure, administering a LMWH in a prophylactic dose until the target INR is observed in two following measurements.（Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1258
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1258.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In specific patients unable to take oral medication, postoperative bridging of VKA with a LMWH in a therapeutic dose could be started within 48 to 72 h after the procedure, once haemostasis has been secured.（Evidence level: low；Recommendation grade: weak）
[laiyuan] => 对于特殊患者(如不能口服药物)，一旦止血成功，可在术后48 ~ 72小时内开始使用治疗剂量的LMWH进行VKA术后桥接治疗。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于特殊患者(如不能口服药物)，一旦止血成功，可在术后48 ~ 72小时内开始使用治疗剂量的LMWH进行VKA术后桥接治疗。（证据级别：低；推荐强度：弱推荐）
In specific patients unable to take oral medication, postoperative bridging of VKA with a LMWH in a therapeutic dose could be started within 48 to 72 h after the procedure, once haemostasis has been secured.（Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1259
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1259.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => In VKA-treated patients undergoing an emergency moderate-to-high bleeding-risk procedure, we recommend that INR must be measured on the patient’s admission to hospital, with the administration of four-factor PCC to reverse VKA anticoagulant effects (at an initial dose of 25 IU factor IX per kg at an INR of 4) over the transfusion of plasma.（Evidence level: moderate；Recommendation grade: strong）
[laiyuan] => 对于使用VKA治疗并接受中至高出血风险急诊手术的患者，必须在患者入院时测定INR，并给予四因子凝血酶原复合物浓缩物(4F-PCC)以逆转VKA抗凝作用对于输注血浆的影响(初始剂量为25 IU IX因子·kg-1, INR为4)。（证据级别：中；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于使用VKA治疗并接受中至高出血风险急诊手术的患者，必须在患者入院时测定INR，并给予四因子凝血酶原复合物浓缩物(4F-PCC)以逆转VKA抗凝作用对于输注血浆的影响(初始剂量为25 IU IX因子·kg-1, INR为4)。（证据级别：中；推荐强度：强推荐）
In VKA-treated patients undergoing an emergency moderate-to-high bleeding-risk procedure, we recommend that INR must be measured on the patient’s admission to hospital, with the administration of four-factor PCC to reverse VKA anticoagulant effects (at an initial dose of 25 IU factor IX per kg at an INR of 4) over the transfusion of plasma.（Evidence level: moderate；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1260
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1260.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => If PCC is not available, in bleeding patients where VKA-induced coagulopathy is considered a contributing factor, we recommend the transfusion of plasma 15 to 20 ml kg 1 plus 5 to 10 mg i.v. vitamin K.（Evidence level: low；Recommendation grade: strong）
[laiyuan] => 如果凝血酶原复合物浓缩物（PCC）不可用，对于VKA诱发凝血障碍的出血患者，建议输注血浆15-20 ml·kg-1加5-10mg 维生素K静脉给药。（证据级别：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
如果凝血酶原复合物浓缩物（PCC）不可用，对于VKA诱发凝血障碍的出血患者，建议输注血浆15-20 ml·kg-1加5-10mg 维生素K静脉给药。（证据级别：低；推荐强度：强推荐）
If PCC is not available, in bleeding patients where VKA-induced coagulopathy is considered a contributing factor, we recommend the transfusion of plasma 15 to 20 ml kg 1 plus 5 to 10 mg i.v. vitamin K.（Evidence level: low；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1261
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1261.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that DOACs can be given up to the day before surgery for patients undergoing low-bleeding-risk procedures such as skin surgery, dental and stomatological procedures, gastric and colonic endoscopies (even if biopsy is scheduled but not polypectomies) and most ophthalmological surgery.（Evidence level: low；Recommendation grade: weak）
[laiyuan] => 对于接受低出血风险手术(如皮肤手术、牙科和口腔手术、胃和结肠内镜检查，即使计划进行活检，但不进行息肉切除术)和大多数眼科手术的患者，建议在术前1天停用DOAC。（（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于接受低出血风险手术(如皮肤手术、牙科和口腔手术、胃和结肠内镜检查，即使计划进行活检，但不进行息肉切除术)和大多数眼科手术的患者，建议在术前1天停用DOAC。（（证据级别：低；推荐强度：弱推荐）
We suggest that DOACs can be given up to the day before surgery for patients undergoing low-bleeding-risk procedures such as skin surgery, dental and stomatological procedures, gastric and colonic endoscopies (even if biopsy is scheduled but not polypectomies) and most ophthalmological surgery.（Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1262
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1262.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => we recommend that for rivaroxaban, apixaban and edoxaban, the time from last drug intake to intervention should be 3 days, pending a creatinine clearance (Cockcroft–Gault formula) above 30 ml/min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
[laiyuan] => 对于利伐沙班、阿哌沙班和依度沙班，建议从最后一次服药到手术的时间应为3 d，等待肌酐清除率> 30 ml·min-1。不建议桥接。（证据级别：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于利伐沙班、阿哌沙班和依度沙班，建议从最后一次服药到手术的时间应为3 d，等待肌酐清除率> 30 ml·min-1。不建议桥接。（证据级别：低；推荐强度：强推荐）
we recommend that for rivaroxaban, apixaban and edoxaban, the time from last drug intake to intervention should be 3 days, pending a creatinine clearance (Cockcroft–Gault formula) above 30 ml/min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1263
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1263.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => we recommend that for dabigatran, the time from last drug intake to intervention should be 3 days, if the creatinine clearance is above 50 ml /min , and 5 days if the creatinine clearance is between 30 and 50 ml /min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
[laiyuan] => 对于达比加群，如果肌酐清除率> 50 ml·min-1，建议末次服药至手术的时间为3 d，如果肌酐清除率在30 ~ 50 ml min-1，建议为5 d。（证据级别：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于达比加群，如果肌酐清除率> 50 ml·min-1，建议末次服药至手术的时间为3 d，如果肌酐清除率在30 ~ 50 ml min-1，建议为5 d。（证据级别：低；推荐强度：强推荐）
we recommend that for dabigatran, the time from last drug intake to intervention should be 3 days, if the creatinine clearance is above 50 ml /min , and 5 days if the creatinine clearance is between 30 and 50 ml /min . No bridging is recommended.（Evidence level: low；Recommendation grade: strong）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
Array
(
[id] => 1264
[catid] => 297
[title] => Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/1264.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:24:27
[updatetime] => 2024-01-11 15:24:27
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://pubmed.ncbi.nlm.nih.gov/36855941/
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2023
[guojia] => the European Society of Anaesthesiology and Intens
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest that in severe bleeding patients treated with dabigatran, a specific antidote (idarucizumab) could be considered.（Evidence level: low；Recommendation grade: weak）
[laiyuan] => 对于接受达比加群治疗的严重出血患者，可以考虑使用特效药物——依达赛珠单抗(idarucizumab)。（证据级别：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957867
[_updatetime] => 1704957867
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于接受达比加群治疗的严重出血患者，可以考虑使用特效药物——依达赛珠单抗(idarucizumab)。（证据级别：低；推荐强度：弱推荐）
We suggest that in severe bleeding patients treated with dabigatran, a specific antidote (idarucizumab) could be considered.（Evidence level: low；Recommendation grade: weak）
证据评价方法：GRADE
指南质量等级：B
年份：2023
国家：the European Society of Anaesthesiology and Intens
